Nantes, France, December 19, 2022: InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), dosed the first patient with IFB-088 in combination with riluzole as part of ...